Published in Clin Exp Immunol on December 17, 2009
Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med (2013) 1.06
Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol (2011) 1.01
Bronchoalveolar lavage cell pattern from healthy human lung. Clin Exp Immunol (2012) 0.92
Overexpression of IL-17RC associated with ocular sarcoidosis. J Transl Med (2014) 0.88
Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. Respir Res (2015) 0.86
Activated CD8(+) T cells and NKT cells in BAL fluid improve diagnostic accuracy in sarcoidosis. Lung (2013) 0.82
Management of hypersensivity pneumonitis. Clin Transl Allergy (2013) 0.81
Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immunol (2010) 0.80
Sarcoidosis. N Engl J Med (1997) 11.02
Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med (1997) 8.59
ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis (1999) 3.69
CD69 is an immunoregulatory molecule induced following activation. Trends Immunol (2005) 2.83
T cell subset-specific susceptibility to aging. Clin Immunol (2008) 2.42
Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med (1984) 2.30
Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol (1998) 2.18
Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (1999) 2.08
Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis (1984) 2.02
T cell activation via Leu-23 (CD69). J Immunol (1989) 1.71
Alveolitis: the key to the interstitial lung disorders. Thorax (1982) 1.71
Down-regulation of CD28 expression by TNF-alpha. J Immunol (2001) 1.65
VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol (1985) 1.53
Hypersensitivity pneumonitis: current concepts. Eur Respir J Suppl (2001) 1.50
The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol (1986) 1.48
T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med (2004) 1.47
CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev (2001) 1.34
T lymphocytes compartmentalized on the epithelial surface of the lower respiratory tract express the very late activation antigen complex VLA-1. Clin Immunol Immunopathol (1988) 1.25
Corticosteroid treatment in sarcoidosis. Eur Respir J (2006) 1.13
Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med (2001) 1.12
T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci U S A (1994) 1.11
Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27- human T cells. J Immunol (2000) 1.02
Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax (1999) 1.02
Immune mechanisms in interstitial lung diseases. Allergy (2000) 0.88
Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases. Clin Exp Immunol (1999) 0.87
Evaluation of CD103 as a cellular marker for the diagnosis of pulmonary sarcoidosis. Clin Immunol (2008) 0.86
The lymphocytic alveolitis in sarcoidosis is associated with increased amounts of soluble and cell-bound adhesion molecules in bronchoalveolar lavage fluid and serum. J Intern Med (1998) 0.86
CD4+CD28-T cells are expanded in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.81
Phenotypic and molecular characterization of CD103+ CD4+ T cells in bronchoalveolar lavage from patients with interstitial lung diseases. Cytometry B Clin Cytom (2003) 0.80
Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol (2003) 1.82
Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax (2006) 1.60
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J (2006) 1.56
Nocardiosis: a case series and a mini review of clinical and microbiological features. Neth J Med (2007) 1.54
Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J (2005) 1.48
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. Clin Exp Immunol (2008) 1.30
Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J (2010) 1.19
Corticosteroid treatment in sarcoidosis. Eur Respir J (2006) 1.13
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis (2011) 1.07
Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun (2003) 1.07
Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2012) 1.07
Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2009) 1.02
Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging (2011) 1.00
Variation in IL7R predisposes to sarcoid inflammation. Genes Immun (2009) 0.98
Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol (2009) 0.97
Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis. Clin Exp Immunol (2007) 0.94
Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens (2007) 0.93
Bronchoalveolar lavage cell pattern from healthy human lung. Clin Exp Immunol (2012) 0.92
Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens (2012) 0.92
Rituximab in life threatening antisynthetase syndrome. Rheumatol Int (2009) 0.90
Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patients. Clin Exp Immunol (2006) 0.90
Effective Prolonged Therapy with Voriconazole in a Lung Transplant Recipient with Spondylodiscitis Induced by Scedosporium apiospermum. Case Rep Infect Dis (2011) 0.88
Predicting prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2010) 0.87
18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis (2008) 0.87
Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis. Clin Exp Immunol (2011) 0.84
Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokers. Respir Med (2009) 0.84
Pattern of diffusion disturbance related to clinical diagnosis: The K(CO) has no diagnostic value next to the DL(CO). Respir Med (2005) 0.84
Reduction of variability of exhaled nitric oxide in healthy volunteers. Respir Med (2002) 0.81
Response to pneumococcal vaccination in mannose-binding lectin-deficient adults with recurrent respiratory tract infections. Clin Exp Immunol (2014) 0.81
18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2011) 0.81
Effect of variation in ITGAE on risk of sarcoidosis, CD103 expression, and chest radiography. Clin Immunol (2009) 0.81
Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens (2011) 0.81
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin Exp Immunol (2010) 0.81
Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant (2007) 0.80
YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndrome. Sarcoidosis Vasc Diffuse Lung Dis (2013) 0.80
The effect of red cell transfusion on nitric oxide diffusing capacity. Respiration (2005) 0.80
Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Sarcoidosis Vasc Diffuse Lung Dis (1997) 0.80
Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome. Clin Exp Immunol (2008) 0.80
Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immunol (2010) 0.80
Angiotensin II receptor type 1 1166 A/C and angiotensin converting enzyme I/D gene polymorphisms in a Dutch sarcoidosis cohort. Sarcoidosis Vasc Diffuse Lung Dis (2010) 0.80
Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine (2007) 0.79
Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol (2011) 0.79
Alveolar volume determined by single-breath helium dilution correlates with the high-resolution computed tomography-derived nonemphysematous lung volume. Respiration (2005) 0.79
Chlamydia psittaci: a relevant cause of community-acquired pneumonia in two Dutch hospitals. Neth J Med (2016) 0.79
Complement receptor 1 single nucleotide polymorphisms in Czech and Dutch patients with sarcoidosis. Tissue Antigens (2007) 0.77
Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis. Brain Behav Immun (2013) 0.77
CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis (2010) 0.77
Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets. Clin Exp Immunol (2011) 0.77
Therapy in pneumonia: what is beyond antibiotics? Neth J Med (2011) 0.76
No association between interleukin-18 gene polymorphisms and haplotypes in Dutch sarcoidosis patients. Tissue Antigens (2004) 0.76
Genetics of sarcoidosis: role of co-stimulatory genes? Respiration (2005) 0.75
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer (2002) 0.75
Chest Computed Tomography-Based Scoring of Thoracic Sarcoidosis: Inter-rater Reliability of CT Abnormalities. Eur Radiol (2015) 0.75
TIMP-3 promoter gene polymorphisms in BFL. Thorax (2005) 0.75
Primitive neuroectodermal tumor: report of two cases and review of the literature. J Thorac Cardiovasc Surg (2002) 0.75
[Haemoptysis as a complication of Behçet's disease]. Ned Tijdschr Geneeskd (2005) 0.75
Earlobe sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2012) 0.75
Inverse association between sarcoidosis and atopic asthma. Sarcoidosis Vasc Diffuse Lung Dis (1998) 0.75
[Pulmonary alveolar proteinosis: a disease caused by surfactant accumulation, and new treatment with sargramostim]. Ned Tijdschr Geneeskd (2008) 0.75